Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early tirofiban after intravenous thrombolysis for disabling acute ischemic stroke
ChiCTR2400087813Phase 4Recruiting
- Sponsor
- Guangxi Medical University Second Affiliated Hospital
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tirofiban in ischemic stroke (2 arms), sponsored by Guangxi Medical University Second Affiliated Hospital. Primary endpoints: Early neurological deterioration within 72 hours and Symptomatic intracranial hemorrhage within 72 hours. Started Aug 2024; status: recruiting.
02
Drugs
tirofiban
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2400087813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087813.